Ayad M, Karanth S, Patel B. A quality improvement initiative to determine the outcomes of creating an automated repeat lactate order in sepsis patients with lactate levels greater than or equal 2 mmol/l. Poster presented at the CHEST 2018 Annual Meeting; October 2018. [abstract] Chest. 2018 Oct; 154(4):321A. doi: 10.1016/j.chest.2018.08.294
Simou E, Leonardi-Bee J, Britton J. The effect of alcohol consumption on the risk of ARDS: a systematic review and meta-analysis. Chest. 2018 Jul;154(1):58-68. doi: 10.1016/j.chest.2017.11.041
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Sanchez-de-la-Torre A, Soler X, Barbe F, Flores M, Maisel A, Malhotra A, Rue M, Bertran S, Aldoma A, Worner F, Valls J, Lee CH, Turino C, Galera E, de Batlle J, Sanchez-de-la-Torre M, Spanish Sleep Network. Cardiac troponin levels in patients with acute coronary syndrome and sleep apnea: a pilot study. Chest. 2018 Feb;153(2):329-38. doi: 10.1016/j.chest.2017.06.046
Donohue J, Ganapathy V, Davenport E, Nelson L, Zhao X. COPD-related hospitalizations associated with arformoterol tartrate treatment among patients receiving concomitant tiotropium (TIO) therapy: post hoc analyses from a 52-week randomized, controlled study. Poster presented at the CHEST 2016 Annual Meeting; October 24, 2016. Los Angeles, CA. [abstract] Chest. 2016 Oct; 150(4_S). doi: 10.1016/j.chest.2016.08.990
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Rodriguez E, Ferrer J, Marti S, Zock JP, Plana E, Morell F. Impact of occupational exposure on severity of COPD. Chest. 2008 Dec;134(6):1237-43.
Massanari M, Sacco P, Kianifard F, Maykut R, Zeldin R. Addition of omalizumab improved measures of impairment associated with moderate-severe persistent asthma. Poster presented at the American College of Chest Physicians; October 2008. Philadelphia, PA. [abstract] Chest. 134(4_MeetingAbstracts):95001.
Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelson HS. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005 Oct;128(4):1910-20. doi: 10.1378/chest.128.4.1910
Johannes CB, Schneider GA, Dube TJ, Alfredson TD, Davis KJ, Walker AM. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest. 2005 Jan 1;127(1):89-97.